Academic article

• Riechelmann, Rachel P.; Torrezan, Giovana T.; Bergsland, Emily et al. (2025). Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study. (external link)
• Sorbye, Halfdan; Hjortland, Geir Olav; Vestermark, Lene Weber et al. (2025). Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study. (external link)
• Ree, Anne Hansen; Benth, Jurate Saltyte; Hamre, Hanne Mari et al. (2024). First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial. (external link)
• Hamfjord, Julian; Guren, Tormod Kyrre; Glimerius, Bengt et al. (2024). Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer. (external link)
• Sorbye, Halfdan; Hjortland, Geir Olav; Vestermark, L.W. et al. (2024). NETest in advanced high-grade gastroenteropancreatic neuroendocrine neoplasms. (external link)
• Kinos, Sampsa; Hagman, Helga; Halonen, Päivi et al. (2024). Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study). (external link)
• Ree, Anne Hansen; Høye, Eirik; Esbensen, Qin Ying et al. (2024). Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade. (external link)
• Elvebakken, Hege; Venizelos, Andreas; Perren, Aurel et al. (2024). Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms. (external link)
• Osterlund, Emerik; Ristimäki, Ari; Mäkinen, Markus J. et al. (2023). Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts. (external link)
• Knappskog, Stian; Grob, Tobias; Venizelos, Andreas et al. (2023). Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma. (external link)
• Sorbye, Halfdan; Grande, Enrique; Pavel, Marianne et al. (2023). European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. (external link)
• Papantoniou, Dimitrios; Grönberg, Malin; Thiis-Evensen, Espen et al. (2023). Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort. (external link)
• Elvebakken, Hege; Hjortland, Geir Olav; Garresori, Herish et al. (2023). Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms. (external link)
• Liposits, Gabor; Winther, Stine B.; Ryg, Jesper et al. (2023). The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer – A post-hoc exploratory analysis of the randomized NORDIC9-study. (external link)
• Steen, Synne Wollen; Sorbye, Halfdan; Jazbani, Mehran et al. (2023). Takotsubosyndrom under behandling med fluorouracil. (external link)
• Morken, Siren; Langer, Seppo W.; Sundlöv, Anna et al. (2023). Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms. (external link)
• Venizelos, Andreas; Sorbye, Halfdan; Elvebakken, Hege et al. (2023). Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. (external link)
• Larsen, Stein Gunnar; Goscinski, Mariusz Adam; Dueland, Svein et al. (2022). Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. (external link)
• Meltzer, Sebastian; Negård, Anne; Bakke, Kine Mari et al. (2022). Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer. (external link)
• Liposits, Gabor; Skuladottir, Halla; Ryg, Jesper et al. (2022). The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, dNLR, YKL-40, and IL-6) in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy—The Randomized NORDIC9-Study. (external link)
• Falk, Philip; Severin, Mira; Berglund, Åke et al. (2022). Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer. (external link)
• Osterlund, Emerik; Ristimäki, Ari; Kytölä, Soili et al. (2022). KRAS-G12C mutation in one real-life and three population-based Nordic cohorts of metastatic colorectal cancer. (external link)
• Liposits, Gabor Isivan; Ryg, Jesper; Skuladottir, Halla et al. (2022). Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy – The randomized NORDIC9-study. (external link)
• Thiis-Evensen, Espen; Kjellman, Magnus; Knigge, Ulrich et al. (2022). Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors. (external link)
• Stokmo, Henning Langen; Aly, Mahmoud; Lothe, Inger Marie Bowitz et al. (2022). Volumetric parameters from [18F]FDG PET/CT predicts survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. (external link)
• Dasari, Arvind; Shen, Chan; Devabhaktuni, Anjali et al. (2022). Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. (external link)
• Aasebø, Kristine Øverås; Bruun, Jarle; Bergsland, Christian Holst et al. (2022). Prognostic role of tumour infiltrating lymphocytes and macrophages in relation to tumour MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients. (external link)
• Osterlund, P.; Kinos, S.; Pfeiffer, P. et al. (2022). Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. (external link)
• Pommergaard, Hans-Christian; Nielsen, Kirstine; Sorbye, Halfdan et al. (2021). Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms. (external link)
• Venizelos, Andreas; Elvebakken, Hege; Perren, Aurel et al. (2021). The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. (external link)
• Rinke, Anja; Auernhammer, Christoph J.; Bodei, Lisa et al. (2021). Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?. (external link)
• Hicks, Rodney J.; Dromain, Clarisse; Herder, Wouter De et al. (2021). ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. (external link)
• Liposits, Gabor; Eshoj, Henrik; Möller, Sören et al. (2021). Quality of life in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy—the randomized NORDIC9-study. (external link)
• Larsen, Stein Gunnar; Goscinski, Mariusz Adam; Dueland, Svein et al. (2021). Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. (external link)
• Hamfjord, Julian; Guren, Tormod Kyrre; Glimelius, Bengt et al. (2021). Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer. (external link)
• Janson, Eva Tiensuu; Knigge, Ulrich; Dam, Gitte et al. (2021). Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. (external link)
• Vogt, Elinor Margrethe Chelsom; Hammerling, Katrin; Sorbye, Halfdan et al. (2021). Feminizing adrenal tumor identified by plasma steroid profiling. (external link)
• Dam, Gitte; Grønbæk, Henning; Sorbye, Halfdan et al. (2020). Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors. (external link)
• Sorbye, Halfdan; Meyer, Liv Sylvi; Mordal, Kjerstin Elisabeth Skrede et al. (2020). Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours. (external link)
• Kjellman, Magnus; Knigge, Ulrich; Welin, Staffan et al. (2020). A plasma protein biomarker strategy for detection of small intestinal neuroendocrine tumors. (external link)
• Elvebakken, Hege; Perren, Aurel; Scoazec, Jean-Yves et al. (2020). A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. (external link)
• Ali, Abir Salwa; Perren, Aurel; Lindskog, Cecilia et al. (2020). Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3. (external link)
• Ali, Abir Salwa; Langer, Seppo W.; Federspiel, Birgitte et al. (2020). PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. (external link)
• Nunes, Luís; Aasebø, Kristine; Mathot, Lucy et al. (2020). Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. (external link)
• Aasebø, Kristine; Dragomir, Anca; Sundström, Magnus et al. (2020). CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup. (external link)
• Sorbye, Halfdan; Baudin, Eric; Borbath, Ivan et al. (2019). Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). (external link)
• Winther, Stine Brændegaard; Liposits, Gabor Isivan; Skuladottir, Halla et al. (2019). Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. (external link)
• Hamfjord, Julian; Guren, Tormod Kyrre; Dajani, Olav et al. (2019). Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. (external link)
• Aasebø, Kristine; Dragomir, Anca; Sundström, Magnus et al. (2019). Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients. (external link)
• Joranger, Pål; Nesbakken, Arild; Sorbye, Halfdan et al. (2019). Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. (external link)
• Carlsen, Esben Andreas; Fazio, Nicola; Granberg, Dan et al. (2019). Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: A multicenter cohort study. (external link)
• Mezheyeuski, Artur; Pontén, Fredrik; Edqvist, Per-Henrik et al. (2019). Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. (external link)
• Bjørnelv, Gudrun Maria Waaler; Dueland, Svein; Line, Pål Dag et al. (2018). Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver.. (external link)
• Dasari, Arvind; Mehta, Kathan; Byers, Lauren Averett et al. (2018). Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. (external link)
• Goey, Kaitlyn K.H.; Sorbye, Halfdan; Glimelius, Bengt et al. (2018). Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. (external link)
• Thomsen, Maria; Skovlund, Eva; Sorbye, Halfdan et al. (2018). Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. (external link)
• Ali, Abir Salwa; Grönberg, Malin; Langer, Seppo Wang et al. (2018). Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). (external link)
• Sorbye, Halfdan; Baudin, Eric; Perren, Aurel (2018). The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: Well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond. (external link)
• Garcia-Carbonero, Rocio; Rinke, Anja; Valle, Juan W et al. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Chemotherapy. (external link)
• Mezheyeuski, Artur; Strell, Carina; Hrynchyk, Ina et al. (2017). Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. (external link)
• Guren, Tormod Kyrre; Thomsen, Maria; Kure, Elin H. et al. (2017). Cetuximab in treatment of metastatic colorectal cancer: Final survival analyses and extended RAS data from the NORDIC-VII study. (external link)
• Thomsen, Maria; Guren, Marianne; Skovlund, Eva et al. (2017). Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. (external link)
• Galleberg, Renate Berget; Knigge, Ulrich Peter; Janson, Eva M. Tiensuu et al. (2017). Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. (external link)
• Dumanski, Jan P.; Rasi, Chiara; Björklund, Peyman et al. (2017). A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors. (external link)
• Angelsen, Jon-Helge; Horn, Arild; Sorbye, Halfdan et al. (2017). Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway. (external link)
• Pavel, Marianne; Valle, Juan W; Eriksson, Barbro et al. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Biotherapy and Novel Targeted Agents. (external link)
• Winther, Stine Brændegaard; Österlund, Pia; Berglund, Åke et al. (2017). Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. (external link)
• Ali, Abir Salwa; Grönberg, Malin; Federspiel, Birgitte et al. (2017). Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. (external link)
• Labori, Knut Jørgen; Lassen, Kristoffer; Hoem, Dag et al. (2017). Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial. (external link)
• Siesing, Christina; Sorbye, Halfdan; Dragomir, Anca et al. (2017). High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. (external link)
• Perren, Aurel A.; Couvelard, Anne; Scoazec, Jean-Yves et al. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification. (external link)
• Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen et al. (2016). A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. (external link)
• Mezheyeuski, Artur; Lindh, Maja Bradic; Guren, Tormod Kyrre et al. (2016). Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. (external link)
• Thomsen, Maria; Kersten, Christian; Sorbye, Halfdan et al. (2016). Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. (external link)
• Løes, Inger Marie; Immervoll, Heike; Sorbye, Halfdan et al. (2016). Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. (external link)
• Tarpgaard, Line Schmidt; Ørum-Madsen, Maj Sofie; Christensen, Ib Jarle et al. (2016). TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. (external link)
• Sveen, Anita; Løes, Inger Marie; Alagaratnam, Sharmini et al. (2016). Intra-patient inter-metastatic genetic heterogeneity in colorectal cancer as a key determinant of survival after curative liver resection. (external link)
• Winther, S.B.; Østerlund, P.; Berglund, Å et al. (2016). NORDIC9: A randomized phase II trial exploring treatment of older patients with metastatic colorectal cancer (mCRC) by comparing full dose monotherapy (S-1 followed by irinotecan) with reduced combination regimen (S-1/oxaliplatin followed by S-1/irinotecan). (external link)
• Garcia-Carbonero, Rocio; Sorbye, Halfdan; Baudin, Eric et al. (2016). ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. (external link)
• Winther, Stine Brændegaard; Zubcevic, Kanita; Qvortrup, Camilla et al. (2016). Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. (external link)
• Österlund, Pia; Sorbye, Halfdan; Pfeiffer, Per et al. (2016). Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. (external link)
• Haugvik, Sven-Petter; Janson, Eva Tiensuu; Osterlund, Pia et al. (2016). Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. (external link)
• Tarpgaard, Line Schmidt; Christensen, Ib J.; Høyer-Hansen, Gunilla et al. (2015). Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. (external link)
• Pfeiffer, Per; Sorbye, Halfdan; Qvortrup, Camilla et al. (2015). Maintenance therapy with cetuximab every second week in the first-line treatment of metastatic colorectal cancer: the NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group. (external link)
• Tanis, Erik; Julié, Catherine; Emile, Jean-Francois et al. (2015). Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. (external link)
• Sorbye, Halfdan; Dragomir, Anca; Sundström, Magnus et al. (2015). High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. (external link)
• Joranger, Pål; Nesbakken, Arild; Hoff, Geir et al. (2015). Modeling and Validating the Cost and Clinical Pathway of Colorectal Cancer. (external link)
• Angelsen, Jon-Helge; Viste, Asgaut; Løes, Inger Marie et al. (2015). Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases. (external link)
• Poulsen, Laurids Ø.; Qvortrup, Camilla; Pfeiffer, Per et al. (2015). Review on adjuvant chemotherapy for rectal cancer-why do treatment guidelines differ so much?. (external link)
• Tanis, Erik; Nordlinger, Bernard; Mauer, Murielle et al. (2014). Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. (external link)
• Janson, Eva Tiensuu; Sorbye, Halfdan; Welin, Staffan et al. (2014). Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. (external link)
• Tarpgaard, Line Schmidt; Guren, Tormod Kyrre; Glimelius, Bengt et al. (2014). Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: Results from the NORDIC VII Study. (external link)
• Nordlinger, Bernard; Sorbye, Halfdan; Glimelius, Bengt et al. (2013). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. (external link)
• Sorbye, Halfdan; Småstuen, Milada Cvancarova; Qvortrup, Camilla et al. (2013). Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. (external link)
• Sorbye, Halfdan; Welin, Staffan; Langer, Seppo W. et al. (2013). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. (external link)
• Trønnes, Håvard; Haugland, Hans Kristian; Bekassy, Albert N. et al. (2012). Small Cell Lung Cancer in a 14-Year-Old Girl. (external link)
• Sorbye, Halfdan; Mauer, Murielle; Gruenberger, Thomas et al. (2012). Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983). (external link)
• Cavalli-Björkman, Nina; Qvortrup, Camilla; Sebjørnsen, Sigrunn et al. (2012). Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone. (external link)
• Tveit, Magne Kjell; Guren, Tormod Kyrre; Glimelius, Bengt et al. (2012). Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII Study. (external link)
• Roy, Arunabha; Cunningham, David; Hawkins, Robert et al. (2012). Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. (external link)
• Fassnacht, Martin; Terzolo, Massimo; Allolio, Bruno et al. (2012). Combination Chemotherapy in Advanced Adrenocortical Carcinoma. (external link)
• Kjersem, Janne Beathe; Andersen, Tone Ikdahl; Guren, Tormod Kyrre et al. (2012). Let-7 miRNA-binding site polymorphism in the KRAS 3 ' UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab. (external link)
• Welin, Staffan; Sørbye, Halfdan; Sebjørnsen, Sigrunn et al. (2011). Clinical effect of Temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. (external link)
• Glimelius, Bengt; Garmo, Hans; Berglund, Åke et al. (2011). Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. (external link)
• Janson, ET; Sørbye, Halfdan; Welin, S et al. (2010). Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. (external link)
• Sørbye, Halfdan; Pfeiffer, P; Cavalli-Bjorkman, N et al. (2009). Clinical Trial Enrollment, Patient Characteristics, and Survival Differences in Prospectively Registered Metastatic Colorectal Cancer Patients. (external link)
• Glimelius, Bengt; Sørbye, Halfdan; Balteskard, L et al. (2008). A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. (external link)
• Qvortrup, C; Yilmaz, M; Øgreid, Dagfinn et al. (2008). Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. (external link)
• Sørbye, Halfdan (2008). Prognostic clinical factors in metastatic colorectal cancer. (external link)
• Nordlinger, B; Gruenberger, T; Sørbye, Halfdan et al. (2008). Surgery vs surgery and chemotherapy for colorectal liver metastases. (external link)
• Nordlinger, Bernard; Sørbye, Halfdan; Glimelius, Bengt et al. (2008). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. (external link)
• Hovdenak, Nils; Sørbye, Halfdan; Dahl, Olav (2005). SSucralfate does not ameliorate acute radiation proctitis: Randomised study and meta-analysis. (external link)
• Sørbye, Halfdan; Glimelius, Bengt; Berglund, Å et al. (2004). Multicentre phase II study of Nordic 5-fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. (external link)
• Sørbye, Halfdan; Dahl, Olav (2004). Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. (external link)
• Sørbye, Halfdan; Dahl, Olav (2003). Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to Oxaliplatin combination chemotherapy: Implications for tumor marker monitoring and guidelines. (external link)
• Hovdenak, Nils; Karlsdottir, Åsa; Sørbye, Halfdan et al. (2003). Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. (external link)
• Sørbye, Halfdan; Dahl, Olav (2003). Nordic 5-Fluorouracil/Leucovorin bolus schedule combined with Oxaliplatin (Nordic FLOX)as first-line treatment of metastatic colorectal cancer. (external link)
• Øvrebø, Kjell Kåre; Svanes, Knut; Aase, Steinar Torbjørn et al. (2002). Duodenogastric reflux increases the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the antral mucosa of rats. A possible role for mucosal erosions and increased cell proliferation in gastric carsinogenesis. (external link)
• Øvrebø, Kjell Kåre; Svanes, Knut; Aase, Steinar et al. (2002). Gastric mucosa lesions induced by duodenogastric reflux increase the penetration of N-[3H]-methyl-N-nitro-N-nitrosoguanidine into the corpus mucosa of rats. (external link)
• Øvrebø, Kjell Kåre; Aase, Steinar; Grong, Ketil et al. (2002). Ulceration as a possible link between duodenogastric reflux and neoplasms in the stomach of rats. (external link)
• Sørbye, Halfdan; Bruserud, Øystein; Dahl, Olav (2001). Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and hemolysis. Case report. (external link)
• Øvrebø, Kjell Kåre; Svardal, Asbjørn; Kvinnsland, Stener et al. (1999). Glutathione modulation changes the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the gastric mucosa of rats. (external link)
• Sørbye, Halfdan; Jensen, Dag; Dahl, Olav (1998). Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. (external link)
• Sørbye, Halfdan; Jensen, Dag; Dahl, Olav (1998). Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. (external link)
• Øvrebø, Kjell Kåre; Sørbye, Halfdan; Kvinnsland, Stener et al. (1998). Effect of gastric secretion on the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the gastric mucosa of rats. (external link)
• Øvrebø, Kjell Kåre; Sørbye, Halfdan; Svardal, Asbjørn et al. (1997). Glutathione and N-acetylcysteine reduce gastric mucosal blood flow in rats. (external link)
• Sørbye, Halfdan; Guttu, Kristian; Gislason, Hjørtur et al. (1993). Gastric mucosal injury and associated changes in mucosal blood flow and gastric fluid secretion caused by dimethyl sulphoxide (DMSO) in rats. (external link)

Errata

• Sorbye, Halfdan; Hjortland, Geir Olav; Vestermark, Lene Weber et al. (2025). Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study. (external link)
• Lutz, Manfred P.; Zalcberg, John R.; Glynne-Jones, Rob et al. (2016). Erratum: Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" (European Journal of Cancer (2016) 68 (208?209) (S0959804916320780) (10.1016/j.ejca.2016.04.010)). (external link)

Academic literature review

• Sorbye, Halfdan; Kong, Grace; Grozinsky-Glasberg, Simona et al. (2024). PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). (external link)
• Andreatos, Nikolaos; McGarrah, Patrick W.; Sonbol, Mohamad Bassam et al. (2023). Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment. (external link)
• Dam, Gitte; Grønbæk, Henning; Sundlöv, Anna et al. (2023). Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms. (external link)
• Sorbye, Halfdan; Kong, Grace; Grozinsky-Glasberg, Simona (2020). PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). (external link)
• Goey, Kaitlyn K.H.; Mahmoud, Remi; Sorbye, Halfdan et al. (2018). Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. (external link)
• Lutz, Manfred P.; Zalcberg, John R.; Glynne-Jones, Rob et al. (2016). Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer. (external link)
• Sorbye, Halfdan; Strosberg, Jonathan; Baudin, Eric et al. (2014). Gastroenteropancreatic high-grade neuroendocrine carcinoma. (external link)
• Biermann, Martin; Johnsen, Boel; Sørbye, Halfdan et al. (2009). Positronemisjonstomografi ved nevroendokrine svulster. (external link)
• Sørbye, Halfdan; Brændengen, M; Balteskard, L (2008). Palliativ kjemoterapi og strålebehandling ved metastatisk kolorectalkreft. (external link)

Doctoral dissertation

• Elvebakken, Hege; Sørbye, Halfdan; Hofsli, Eva et al. (2023). High-grade digestive neuroendocrine neoplasms. Impact of genetic alterations and morphologicalcharacteristics on outcome of first-line palliative chemotherapy. (external link)
• Sørbye, Halfdan (1994). Penetration of carcinogens into normal and damaged gastric mucosa. (external link)

Poster

• Meltzer, Sebastian; Negård, Anne; Hamre, Hanne Mari et al. (2022). Early radiologic signal of nivolumab responsiveness after short-course oxaliplatin-based chemotherapy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).. (external link)
• Ree, Anne Hansen; Hamre, Hanne Mari; Kersten, Christian et al. (2021). Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study. (external link)
• Joranger, Pål; Nesbakken, Arild; Hoff, Geir et al. (2014). Development and validation of a Norwegian model for colorectal cancer. (external link)
• Sørbye, Halfdan; Glimelius, Bengt; Berglund, Åke et al. (2003). Nordic 5-fluorouracil/folinic acid bolus schedule combined with oxaliplatin (FLOX) as first-line treatment to metastatic colorectal cancer. (external link)
• Guttu, K; Sorbye, Halfdan; Svanes, K. et al. (1993). Effect of restricted hyperaemic response and systemic alkalinization on gastric luminal bicarbonate release and mucosal restitution after hyperomolar damage in the cat.. (external link)

Reader opinion piece

• Sorbye, Halfdan (2019). Ekspertpanel for ny vurdering ved alvorlig sykdom. (external link)
• Sorbye, Halfdan; Mauer, Murielle; Nordlinger, Bernard (2015). Reply to letter: "Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)". (external link)

Academic lecture

• Joranger, Pål; Nesbakken, Arild; Hoff, Geir et al. (2015). Modell for å beregne overlevelse og kostnader av behandling for kolorektal cancer. (external link)
• Glimelius, Bengt; Sørbye, Halfdan; Balteskard, L et al. (2005). A randomised phase III multicenter trial comparing irinotecan in combination with 5FU and folinic acid (FU/FA) given according to the Nordic bolus schedule to irinotecan in combination with 5FU/FA given according to the bolus/infused de Gramont schedule, in patients with metastatic colorectal cancer. (external link)

Academic chapter/article/Conference paper

• Sorbye, Halfdan (2014). Recurrence Patterns After Resection of Liver Metastases from Colorectal Cancer. (external link)
• Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Hoem, Dag et al. (2013). Ultrasound-assisted treatment of an inoperable pancreatic cancer. (external link)
• Telhaug, Ragnar; Varhaug, Jan Erik; Sørbye, Halfdan et al. (2009). Endokrine svulster. (external link)
• Sørbye, Halfdan (2008). The use of Chemotherapy for Neuroendocrine Tumors. (external link)
• Bremnes, RM; Endresen, P; Sørbye, Halfdan (1999). Antimetabolitter. (external link)

Editorial

• Sorbye, Halfdan (2012). Palliative chemotherapy in elderly patients with metastatic colorectal cancer: Do we know how it should be used?. (external link)

Report

• Aaserud, Morten; Kristiansen, Ivar Sønbø; Neilson, Aileen Rae et al. (2007). Helseøkonomisk evaluering av bevacizumab ved metastatisk kolorektalcancer. (external link)

See a complete overview of publications in Cristin.